i

PROPOSAL PROGRAM KREATIVITAS MAHASISWA

AVATAR: Multi Source Powerbank Berbasis Tenaga Air, Angin, dan Sinar
Matahari

BIDANG KEGIATAN:
PKM KARSA CIPTA

Diusulkan oleh:
Bidessa Talfit Ristiyanta; 21060118120053; 2018
Faizhal Dimas Leksono; 21030118130095; 2018
Ian Aditama Putra; 21050118120019; 2018

UNIVERSTAS DIPONEGORO
SEMARANG
2019
 PROPOSAL PROGRAM KREATIVITAS MAHASISWA
AVATAR: Multi Source Powerbank Berbasis Tenaga Air, Angin, dan Sinar
Matahari

BIDANG KEGIATAN:
PKM KARSA CIPTA

Diusulkan oleh:
Bidessa Talfit Ristiyanta; 21060118120053; 2018
Faizhal Dimas Leksono; 21030118130095; 2018
Ian Aditama Putra; 21050118120019; 2018

UNIVERSTAS DIPONEGORO
SEMARANG
2019

i
i
 DAFTAR ISI
HALAMAN SAMPUL
HALAMAN PENGESAHAN PKM-KARSACIPTA
DAFTAR ISI..........................................................................................................iii
DAFTAR GAMBAR .............................................................................................iv
DAFTAR TABEL ...................................................................................................v
CHAPTER I. PENDAHULUAN.............................................................................1
1.1 Latar belakang ...............................................................................................1
1.2 Perumusan Masalah........................................................................................2
1.3 Tujuan Penelitian............................................................................................2
1.4 Luaran Yang Diharapkan...............................................................................3
1.5 Manfaat Penelitian..........................................................................................3
CHAPTER II. TINJAUAN PUSTAKA...................................................................3
2.1 Powerbank......................................................................................................3
2.2 Modul Powerbank..........................................................................................4
2.3 Baterai Ni-MH................................................................................................4
2.4 Panel Surya.....................................................................................................5
2.5 Dinamo DC.....................................................................................................5
CHAPTER III. TAHAP PELAKSANAAN.............................................................6
3.1 Prosedur Pelaksanaan.....................................................................................6
3.1.1 Tempat dan Waktu Pelaksanaan............................................................6
3.1.2 Alat dan Bahan......................................................................................6
3.1.3 Metode yang Digunakan........................................................................6
3.1.4 Prosedur Kerja.......................................................................................6
3.2 Perancangan Sistem Powerbank Avatar ........................................................7
3.2.1 Diagram Blok Sistem Powerbank Avatar.............................................7
3.2.2 Perancangan Perangkat Keras Powerbank Avatar................................8
CHAPTER IV. BIAYA DAN JADWAL KEGIATAN...........................................9
4.1 Anggaran Biaya..............................................................................................9
4.2 Jadwal Kegaitan.............................................................................................9
DAFTAR PUSTAKA ...........................................................................................10
LAMPIRAN ..........................................................................................................11

i
 DAFTAR GAMBAR

Gambar 2.1 Powerbank yang beredar dipasaran 3

Gambar 2.2 Modul Powerbank 4
Gambar 2.3 Baterai Nikel – Metal Hydride AAA 4
Gambar 2.4 Panel Surya Mini 12V 2000mA 5
Gambar 2.5 Dinamo Mini DC 12V Low RPM GA12-N20 5
Gambar 3.1 Diagram Alir Proses Pembuatan Alat 7
Gambar 3.3 Diagram Blok Sistem Powerbank Avatar 8
Gambar 3.3 Diagram Alir Perancangan Perangkat Keras Powerbank Avatar 8
Gambar 5.1 Prototype Powerbank Avatar Tampak Depan 22
Gambar 5.2 Prototype Powerbank Avatar Tampak Samping 22

i
 DAFTAR TABEL

Tabel 3.1 Alat dan Bahan 5

Tabel 3.2 Variabel Pengujian 9
Tabel 4.1 Anggaran biaya 9
Tabel 4.2 Jadwal kegiatan PKM KC 9
Tabel 5.1 Justifikasi anggaran kegiatan 18

i
 Chapter I. Introduction
1.1 Background
On December 31, 2019, several cases of pneumonia of unknown
etiology were reported in Wuhan, China. The outbreak had started in early
December or November (Huang et al., 2020), and the number of cases rose
quickly; more than 80,000 infections were reported in China as of March
15, 2020, including more than 3,000 deaths. At the time of this review
(April 6, 2020), the disease, termed COVID-19 (coronavirus disease 2019),
had become pandemic and spread to more than 203 countries and territories,
including community transmission in countries like the United States,
Germany, France, Spain, Japan, Singapore, South Korea, Iran, and Italy and
a large-scale outbreak with more than 600 cases on the cruise ship Diamond
Princess. As of April 1, more than 870,000 cases and 43,000 deaths had
been reported globally, with rapid growth of numbers in many countries.
The causative agent of the outbreak was swiftly identified as
betacoronavirus with a genomic sequence closely related to that of the
severe acute respiratory syndrome (SARS) coronavirus from 2003, earning
the new virus the name SARS-CoV-2 (Gorbalenya et al., 2020; Wu et al.,
2020; Zhou et al., 2020; Zhu et al., 2020).
COVID-19 has emerged as the most dangerous pandemic threat
through-out the globe since its outbreak during December 2019. It has
become a big challenge for the researchers and virologist to find a solution
for this deadly disease. This is attributed to the fact that COVID-19 is a viral
infection that has been known to have the fastest frequency of
recombination or replication in its positive strand resulting in the quick
formation of new progeny viral cells inside the host cells. It has also been
reported that SARS-CoV-2 has a high rate of mutagenesis and changes in
structure,which has created a barrier for both investigations of the disease
and therapeutic regimens (American Society for Microbiology, 2020).
Recently, few researchers have identified that the SARSCoV- 2 has mainly
two types of strains, which are the ‘L’ and ‘S’ strains. Among these strains
the L strain ismore common and may have evolved from the S strain;
additionally, this L strain has a higher rate of replication inside the human
host cell, which has resulted in the escalation of the infection in limited
time. Hence, it has become a big challenge to analyze the condition and
offer therapy at the short time available. Due to the high mutation rate, it has
been harder to understand the genomic organization and host interaction of
the virus (Habibzadeh and Stoneman, 2020).
The genomic structure of the virus is not the only factor that presents a
great challenge to research, its ability to adapt and survive in different
environmental conditionsmake it nearly impossible to identify itsmode of
survival. It has been earlier reported that the SARS virus can survive at 4 °C

1
with a humidity rate of 20%. The first outbreak of the SARS-CoV-2 was
during the peak of winter, where the environmental temperature was around
2 °C to 10 °C. But since then the virus has infected people and survived in
countries of completely different climatic conditions, making its
demographic association hard to predict. The health care professionals and
equipment are limited and are unable to handle the vast number of patients
who are infected. Moreover, some of the individuals who are infectious are
asymptomatic and continue to travel or gather in social surroundings
infecting more people. These factors pose a challenge for scientists, health-
care professional and government officials to handle and contain the
condition. Government officials in all countries continue tomake efforts to
minimize human contact by facilitating countrywide shutdowns of public
places aswell as various steps have been initiated to ensure the safety of the
people, like social distancing and self-quarantinewhich limits our social
interactions. Thiswill reduce the risk of spreading the COVID-19 to people
by breaking the transmission chain and the influx of new COVID-19 cases
in a given time period (Balachandar et al., 2020).
The development of vaccines for human use can take years, especially
when novel technologies are used that have not been extensively tested for
safety or scaled up for mass production. Because no coronavirus vaccines
are on the market and no large-scale manufacturing capacity for these
vaccines exists as yet, we will need to build these processes and capacities.
Doing this for the first time can be tedious and time consuming. Coalition
for Epidemic Preparedness Innovation (CEPI) has awarded funds to several
highly innovative players in the field, and many of them will likely succeed
in eventually making a SARS-CoV-2 vaccine. However, none of these
companies and institutions have an established pipeline to bring such a
vaccine to late-stage clinical trials that allow licensure by regulatory
agencies, and they do not currently have the capacity to produce the number
of doses needed. An mRNA-based vaccine, which expresses target antigen
in vivo in the vaccinee after injection of mRNA encapsulated in lipid
nanoparticles, co-developed by Moderna and the Vaccine Research Center
at the National Institutes of Health, is currently the furthest along, and a
phase I clinical trial recently started (ClinicalTrials.gov: NCT04283461).
Curevac is working on a similar vaccine but is still in the pre-clinical phase.
Additional approaches in the pre-clinical stage include recombinant-
proteinbased vaccines (focused on the S protein, e.g., ExpresS2ion, iBio,
Novavax, Baylor College of Medicine, University of Queensland, and
Sichuan Clover Biopharmaceuticals), viral-vectorbased vaccines (focused
on the S protein, e.g., Vaxart, Geovax, University of Oxford, and Cansino
Biologics), DNA vaccines (focused on the S protein, e.g., Inovio and
Applied DNA Sciences), live attenuated vaccines (Codagenix with the

2
 Serum Institute of India, etc.), and inactivated virus vaccines. All of these
platforms have advantages and disadvantage, and it is not possible to predict
which strategy will be faster or more successful. Johnson & Johnson (J&J)
(Johnson & Johnson, 2020) and Sanofi (2020) recently joined efforts to
develop SARS-CoV-2 vaccines. However, J&J is using an experimental
adenovirus vector platform that has not yet resulted in a licensed vaccine.
Sanofi’s vaccine, to be made using a process similar to the process used for
their approved Flublok recombinant influenza virus vaccine (Zhou et al.,
2006), is also months, if not years, from being ready for use in the human
population.
It is challenging to apply conventional statistical methods to medical
data with large dimensionality (such as textual and image data). In many
cases, the underlying assumptions of traditional statistical-based methods
are breached when we are dealing with high dimension data with
complexity. Most classic statistical methods are unable to handle Big Data
problems, because emerging infectious disease outbreak related data exists
in various formats and exhibits different limitations and assumptions.
Big Data, AI and machine learning methods have so far shown
promising outcomes in multiple business and industrial settings to reveal
hidden patterns and predict future possibilities. The latest advanced models,
such as deep learning artificial neutral network approaches, have shown
positive results in extracting highly nonlinear structures from a massive
dataset. In a disease related context, recent research using AI methods to
track down rodent reservoirs of future zoonotic diseases [16], predict
Extended-spectrum b-lactamase (ESBL) producing organisms [17], and
control tuberculosis (TB) and gonorrhea disease spreads [18], has been in
place. Public reaction towards disease outbreaks can be difficult to predict.
However, with the availability of Big Data and advent of AI methods, we
are increasingly able to correlate the population behavior with disease
outbreaks.
1.2 Identification Problem
COVID-19 (coronavirus disease 2019), had become pandemic and
spread to more than 203 countries and territories, including community
transmission in countries like the United States, Germany, France, Spain,
Japan, Singapore, South Korea, Iran, and Italy and a large-scale outbreak
with more than 600 cases on the cruise ship Diamond Princess. As of April
1, more than 870,000 cases and 43,000 deaths had been reported globally,
with rapid growth of numbers in many countries. The causative agent of the
outbreak was swiftly identified as betacoronavirus with a genomic sequence
closely related to that of the severe acute respiratory syndrome (SARS)
coronavirus from 2003.
COVID-19 has become a big challenge for the researchers and
virologist to find a solution for this deadly disease. This is attributed to the
fact that COVID-19 is a viral infection that has been known to have the
fastest frequency of recombination or replication in its positive strand

3
 resulting in the quick formation of new progeny viral cells inside the host
cells. It has also been reported that SARS-CoV-2 has a high rate of
mutagenesis and changes in structure,which has created a barrier for both
investigations of the disease and therapeutic regimens
The development of vaccines for human use can take years, especially
when novel technologies are used that have not been extensively tested for
safety or scaled up for mass production. Because no coronavirus vaccines
are on the market and no large-scale manufacturing capacity for these
vaccines exists as yet, we will need to build these processes and capacities.
The furthest along vaccine is co-developed by Moderna and the Vaccine
Research Center at the National Institutes of Health and a phase I clinical
trial recently started. It will take months, if not years, from being ready for
use in the human population.
1.3 Objectives
1. Create an integrated system for finding vaccines for pandemic COVID-
19 quickly using artificial intelligence.
2. Conducting mass vaccine tests using artificial intelligence.
1.4 Expected Output
1. Machine learning to analyze the genome and the body's immune
reaction to produce a new vaccine.
2. Machine learning to analyze vaccine reactions in the body.
1.5 Advantages
1. Get a new vaccine faster
2. Get fast results for vaccine reactions in the body

Chapter II. LITERATURE REVIEW AND CONCEPTUAL FRAMEWORK

2.1 Corona Virus Desease 2019
The novel coronavirus disease 2019 (COVID-19), caused by the
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is in
themidst ofworldwide panic and global health concern since December
2019. As of March 26th, 2020, the World Health Organization (WHO) has
reported that 416,686 and 18,589 death cases have been confirmed
worldwide, and it has spread to 197 countries (WHO, 2020a). With this
emerging battle against this deadly virus, the WHO has strategized to
interrupt human-human contact, isolate patients at early stages, identify and
reduce transmission from the animal source, address crucial mysteries about
the virus and accelerate research, communicate information correctly to the
public and minimize the social and economic impact. At this juncture, it is
tremendously vital to understand the basic mechanism of the virus to
develop specific drugs. Currently, it has been established that SARS-CoV-2
shares sequence homology with the SARS-CoV and a bat coronavirus
(Gorbalenya, 2020). Despite its similarity to SARS-CoV, its transmission
efficiency and diagnostic methods are rather different. The distinguishing
factor is probably the nucleotide changes in the spike (S) protein and its

4
 receptor-binding domain (RBD) (Kannan et al., 2020; Coutard et al., 2020;
Wan et al., 2020). Currently, the treatments include Lopinavir/Ritonavir and
supportive care, as this is primarily dependent on the severity of the illness.
From a research standpoint, various drugs are being developed at an
extremely quick pace and new targets are being identified every day, and
also numerous drugs are also undergoing clinical trials. Researches are very
curious about how to provide the best protection to the public before a
vaccine can bemade available (Balachandar et al., 2020). Indian medicinal
herbs are a promising field for treatment of various illnesses (Gomathi et al.,
2020). Ayurveda and Siddha practices originated in India and are still
widely used among the Indian population. By identifying certain
phytocompounds, it is possible to effectively characterize medicinal herbs
that could help to alleviate the infection. Hence, by repurposing the Indian
medicinal plants, more innovative treatment options can be penned down for
their role in defeating this viral transmission. At a time of worldwide
anxiety, it is imperative to find long term solutions to prevent the
transmission of such pandemics. So, it's time for all the citizens to join
hands together to fight against coronavirus by practicing self-hygiene and
social distancing (Balachandar et al., 2020). In this review, the structure,
immunological influence, mechanism of action of the SARS-CoV-2
infection in the human host cell, the availability of disease-specific drugs,
ongoing clinical trials, recent diagnostics and the potential use of certain
Indianmedicinal herbs for the effective treatment of COVID-19 has been
discussed. Through this review, we suggest that the Indian
traditionalmedicinal herbsmay be a beneficial step to combat viruses like the
SARS-CoV-2.
2.2 Brief of Coronavirus
Coronaviruses, having a total of 39 species under the broad realmof
Riboviria, belong to the family Coronaviridae, suborder Cornidovirineae
and order Nidovirales (Gorbalenya et al., 2020). All the SARS-CoV fall
under the species Severe acute respiratory syndrome-related coronavirus
and genus Beta-coronavirus.Most of the species under this head are enzootic
and only a few of these species infect humans (Schoeman and Fielding,
2019). Currently, seven human CoVs (HCoVs) have been confirmed.
Specifically, they are named as Human coronavirus NL63 (HCoV-NL63)
and Human coronavirus 229E (HCoV-229E), which belong to the alpha-
coronavirus genus; whereas Human coronavirus OC43 (HCoV-OC43),
Human coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and Middle
East respiratory syndrome coronavirus (MERS-CoV), belong to the beta-
coronavirus genus. HCoV-229E, HCoVNL63, HCoV-HKU1 and HCoV-
OC43 strains of coronavirus cause mild respiratory diseases in humans. The
SARS-CoV-2 is a zoonotic virus that belongs to the Coronaviridae family
that can infect human and several animal species (Lu et al., 2020). The
SARS-CoV-2 belongs to the subgenus Sarbecovirus andmostly resembles a
bat coronavirus,with which it shares 96.2% sequence homology (Chan et al.,
2020a). Currently, it is thought that SARS-CoV-2 has been introduced to
human by an unidentified intermediary animal and then it has spread from
human-to-human.

5
 Human coronaviruses are predominantly concomitant with upper
respiratory tract illnesses ranging from mild to moderate including common
cold. Most of the people may be infected with one or more of these viruses
at some point in their lifetime (Killerby et al., 2018). The SARS-CoV
andMERS-CoV are the twomajor causes of severe pneumonia in human
(Song et al., 2019). A comparative analysis of the symptoms
among COVID-19, SARS, MERS and common flu has been explained
(Table.1). The world observed the sudden emergence of COVID-19 in 2019.
The exact origin of the virus, continues to remain as a mystery, to
researchers worldwide. Investigations need to be carried out to pinpoint the
exact source of infection. TheWHO, on February 11, 2020, officially named
the viral disease COVID-19 (Jiang et al., 2020; Guarner, 2020). The
Coronavirus Study Group of the International Committee on Taxonomy of
Viruses named the newpathogen as SARS-CoV- 2 (Gorbalenya, 2020). The
predecessor SARS-CoV first emerged in 2002.

Table 1 Symptomatic comparison of COVID-19, SARS, MERS and

Common.
Diseases Symptom Onset Incubatio Recovery Transmissio Complications Treatments if available
s of n n if any
disease period of disease

Novel Fever Sudden 2–14 days 2–8 weeks Human to Acute No vaccines available, only
Coronavirus Cough after Human pneumonia, symptoms can be treated.
(COVID-19) Shortness of exposure septic shock,
Breath respiratory
Fatigue failure in
adverse
condition.
Severe Fever Sudden 2–7 days 5–6 weeks Human to Heart, Liver and Breathing ventilator to
Acute Dry Cough after Human Respiratory deliver
Respiratory Headache exposure failure in oxygen.
Syndrome Difficulty in adverse Pneumonia treating
(SARS) breathing condition. antibiotics
Muscle Antiviral medicines
aches Steroids to reduce lung
Loss of swelling
appetite
Diarrhoea
Middle East Fever Sudden 5–6 days 6–7 weeks Human to Acute Treatment only for
Respiratory Chills after Human pneumonia symptoms
Syndrome Diarrhoea exposure Kidney failure in such as Fluids replacement
(MERS) Nausea adverse Oxygen therapy.
Vomiting condition.
Congestion
Sneezing
Sore throat
Common flu Runny or Gradual 2–3 days 7–10 days Human to Extremely rare Symptoms can be treated
Stuffy nose after Human or None by medication.
Sneezing exposure
Sore throat
Mild
Headache
Low grade
fever

6
 During its course of infection from 2002 to 2003, 774 deaths were
recorded out of the 8000+ infections spread across 37 countries (Peiris et al.,
2004). This was closely followed by the emergence of MERS-CoV at Saudi
Arabia in 2012, which caused 858 deaths among the 2494 known infected
cases (Zaki et al., 2012). Similar to its antecedents, the SARS-CoV-2
appeared in December 2019 from the animal kingdom and spread to human
populations. The COVID-19 is known to show symptoms slowly over an
incubation period of around 2 weeks. During this time the virus replicates in
the upper and lower respiratory tract, forming lesions (Chan et al., 2020b).
The general symptoms observed in the infected individuals are fever, cough,
dyspnoea and lesion in the lungs (Huang et al., 2020). In the advanced stage,
the symptoms of this virus show pneumonia which progresses to severe
pneumonia and acute respiratory distress syndrome (ARDS) which results in
to the need for life-support to sustain the patient's life (Heymann and
Shindo, 2020).

2.3 Baterai Ni-MH

2.4 Panel Surya
2.5 Dinamo DC
Chapter III. METODE PELAKSANAAN
3.1 Prosedur Pelaksanaan
3.1.1 Tempat dan Waktu Pelaksanaan
3.1.2 Alat dan Bahan
3.1.3 Metode yang Digunakan
3.1.4 Prosedur Kerja
3.2 Perancangan Sistem Multi Source Powerbank
3.2.1 Diagram Blok Sistem Multi Source Powerbank
3.2.2 Perancangan Perangkat Keras Sistem Powerbank Avatar
3.2.3 Pengujian dan Analisis
Chapter IV. BIAYA DAN JADWAL KEGIATAN
4.1 Anggaran Biaya
Tabel 4.1 Anggaran Biaya
No Jenis Pengeluaran Biaya
1. Perlengkapan yang diperlukan Rp 5.086.000
2. Bahan habis pakai Rp 785.000
3. Biaya perjalanan Rp 750.000
4. Biaya lain – lain Rp 5.729.000
Total Biaya Rp 12.350.000
4.2 Jadwal Kegiatan
Tabel 4.2 Jadwal kegiatan PKM KC
No Bulan Bulan Bulan Bulan Bulan
Kegiatan
1 2 3 4 5
1 Studi Pustaka
2 Persiapan alat dan bahan

7
3 Perancangan dan pembuatan
4 Menguji tiap sistem penyusun
alat
5 Melakukan karakterisasi alat
6 Penyusunan laporan

8
 DAFTAR PUSTAKA
Bahari, Syamsul. 2015. Analisis Pembangkit Listrik Tenaga Angin di Desa
Sungai Nibung Kecamatan Teluk Pakedai Kabupaten Kubu Raya. Tugas
Akhir. Jurusan Teknik Elektro.Universitas Tanjungpura.
Bernard, P., & Lippert, M. 2014. Chapter 14 – nickel–cadmium and nickel–
metal hydride battery energy storage. Electrochemical Energy Storage for
Renewable Sources and Grid Balancing.
Donnel, Henri. 2005. Kupas Tuntas Hardware Handphone. Semarang: Penerbit
Vyctoria.
Gottlieb, Irving. 1997. Practical Electric Motor Handbook. Great Britain: Biddles
Ltd.
Gunawan, Arif., Oktafeni , Arisco., & Khabzli, Wahyuni. 2013. Pemantauan
Pembangkit Listrik Tenaga Mikrohidro. Jurnal Rekayasa Elektrika, 10(4),
202-206.
Hurley, Philip. 2006. Build Your Own Solar Panel. minister hill road: Wheelock
Mountain Publication.
Mulyanta, Edi. 2003. Kupas Tuntas Telepon Selular Anda.Yogyakarta:Penerbit
Andi.
Ying, T. K., Gao, X. P., Hu, W. K., Wu, F., & Noréus, D. 2006. Studies on
rechargeable NiMH batteries. International Journal of Hydrogen Energy,
31(4), 525-530.
Zhang, C., Jiang, J., Gao, Y., Zhang, W., Liu, Q., & Hu, X. 2017. Charging
Optimization in Lithium-Ion Batteries Based on Temperature Rise and
Charge Time. Applied Energy, 194, 569–577.

9
Lampiran 2. Justifikasi Anggaran Kegiatan
Tabel 5.1 Justifikasi Anggaran Kegiatan
Harga Satuan
No Jenis Perlengkapan Volume Nilai (Rp.)
(Rp.)
1. Modul Powerbank
4 Buah 65.000 260.000
Dual USB 5V
2. XL6009 Modul
4 Buah 32.000 128.000
Converter
3. Eneloop 2500 mAh 2 Pak 120.000 240.000
4. Baling Baling Lipat
4 Buah 100.000 400.000
CW CCW
5. Dinamo GA12-N20 2 Buah 110.000 220.000
6. ZHC405 Panel Surya
1 Buah 115.000 115.000
Mini 12V
7. Kabel Serabut 1 Pak 30.000 30.000
8. Modul USB
2 Buah 7.500 15.000
9. Solder 1 Buah 25.000 25.000
10. Timah 10m 2 Buah 12.000 24.000
11. Lem Tembak 1 Buah 17.000 17.000
12. Multimeter
1 Buah 170.000 170.000
BEST9205
13. 3D Printing 2 Buah 300.000 600.000
14. Fast Magnetic
4 Buah 73.000 292.000
Charger Cable USB
15. P31 Pro 3800 mAh 2 Buah 1.200.000 2.400.000
16. Powerbank 10000
1 Buah 150.000 150.000
mAh
Sub Total (Rp.) 5.086.000
Harga Satuan
No Bahan Habis Pakai Volume Nilai (Rp.)
(Rp)
1. Timah Solder 1 Buah 148.500 148.500
2. Tang Linesman plier 1 Buah 58.500 58.500
3. Bor Mini 1 Buah 280.000 280.000
4. Meteran Fiberglass 1 Buah 45.000 45.000
5. Penggaris besi 1 Buah 28.000 28.000
6. Obeng 1 Buah 35.000 35.000
7. Amplas Kasar 1 Buah 25.000 25.000
8. Amplas Halus 3 Buah 10.000 30.000
9. Pasta Solder 6 Buah 10.000 60.000
10 Isi Lem Tembak 3 Pak 25.000 75.000
Sub Total (Rp.) 785.000
Harga Satuan
No Perjalanan Volume Nilai (Rp.)
(Rp)
1. Meguji alat di 10 Kali 50.000 500.000

10
 semarang dan
sekitarnya
2. Pembelian peralatan 5 Kali 50.000 250.000
di semarang
Sub Total (Rp.) 750.000
Harga Satuan
No Lain-lain Kuantitas Nilai (Rp.)
(Rp)
1. Pointer 1 Kali 190.000 190.000
2. Buku besar 1 Kali 25.000 25.000
3. Pulpen 1 pak 35.000 35.000
4. Fotokopi dan print 15 Kali 40.000 600.000
5 Publikasi jurnal 1x 4.879.000 4.879.000
. internasional
Sub Total (Rp.) 5.729.000
1+2+3+4= (Rp.) 12.350.000
(Terbilang “Sebelas Juta Empat Ratus Lima Belas Ribu Rupiah”)

11